Coripren 20mg/10mg 56 tablets — Made in Italy — Free Delivery

Primary arterial hypertension.

1 tablet per day, mainly in the morning (before breakfast for ≥15 minutes).

Hypersensitivity to any active pharmaceutical ingredient, any ACE inhibitor or dihydropyridine calcium antagonist, or any other component of the drug; angioedema (idiopathic, hereditary or transferred in connection with the use of ACE inhibitors); pregnancy or its planning; combined use with drugs containing aliskiren against the background of diabetes mellitus or impaired renal function (GFR 60 ml / min / 1.73 m2); obstruction of the outflow of blood from the left ventricle; heart failure in the systemic circulation (in patients who have not received treatment for this reason); angina pectoris (unstable form); previous myocardial infarction (within 1 month); severe renal dysfunction (creatinine clearance 30 ml / min), also in patients receiving hemodialysis treatment; severe liver dysfunction; combined use of cyclosporine, strong inhibitors of syp 3a4, grapefruit juice.

Decrease in the level of hemoglobin, platelets (150⋅109/l); hypersensitivity; increase in the content of potassium in the blood; anxiety; cephalgia and dizziness (including postural), tinnitus; increased heart rate (90 bpm), palpitation; decrease in blood pressure (90/60 mm Hg), insufficientia vascularis; cough, dryness, sore throat; abdominal pain, nausea, constipation, dyspeptic manifestations, swelling of the lips, speech disorders, xerostomia, diarrhea, inflammation of the gum mucosa; increased activity of aminotransferases; angioedema, facial edema, dermatitis, rashes, urticaria; arthralgia; pollakiuria, the predominance of the night part of diuresis over the day part, increased urine output; impotence; weakness, fatigue, peripheral edema, feeling of heat.

Koripren 20 mg/10 mg is not used for initial therapy of hypertension.

Therapy of elderly patients is determined by the functional state of the kidneys.

Caution is required at the start of therapy in patients with mild to moderate hepatic or renal insufficiency.

C caution is prescribed to patients with coronary artery disease or with cerebrovascular pathology (excessive decrease in blood pressure can cause stroke or myocardial infarction), as well as Short's syndrome without an implanted pacemaker and in patients with left ventricular dysfunction.

Secondary hypotension in the treatment of enalapril is possible in patients with heart failure. Medical supervision is required in patients with severe heart failure against the background of a decrease in the content of sodium in the blood, disorders of renal function, or therapy with high doses of loop diuretics (risk of secondary hypotension).

With a decrease in BCC in hypertensive patients taking enalapril, the likelihood of developing secondary hypotension increases.

If secondary hypotension develops, dose reduction or withdrawal of diuretics and/or enalapril may be required.

In patients with impaired renal function of mild or moderate degree, constant monitoring of the content of creatinine and potassium in the blood plasma is required. An increase in the content of creatinine and potassium in the blood plasma can occur in a number of patients with hypertension who do not have a history of kidney pathology, against the background of the use of a diuretic in combination with enalapril.

Against the background of taking enalapril, the development of renal failure is possible (usually in patients with kidney pathology or with severe impairment of cardiac function), which is reversible when the drug is discontinued.

Scrupulous supervision by the doctor of patients with a stenosis is required. renalis (bilateral or a single functioning kidney) treated with ACE inhibitors, due to the likelihood of impaired renal function or a decrease in blood pressure (90/60 mm Hg. Art.). Treatment begins with low doses with a gradual increase against the background of control of renal function.